Trial Profile
A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Nov 2012
Price :
$35
*
At a glance
- Drugs Imagabalin (Primary) ; Paroxetine
- Indications Generalised anxiety disorder
- Focus Adverse reactions; Therapeutic Use
- 21 Apr 2012 Additional trial location (Germany) added as reported by European Clinical Trials Database.
- 08 May 2009 Actual patient number (363) added as reported by ClinicalTrials.gov.
- 25 Feb 2009 Status changed from recruiting to discontinued. Pfizer has decided to discontinue development of this drug for the treatment of generalised anxiety disorder, as reported in a media release.